Cite
HARVARD Citation
Wang, T. et al. (n.d.). 82P Preliminary analysis of tislelizumab (TIS) and chemotherapy as neoadjuvant therapy for potentially resectable stage IIIA/IIIB non-small cell lung cancer (NSCLC). Immuno-oncology technology. p. . [Online].